Trelagliptin

Drug profile

Key facts

Trelagliptin is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2015. DrugCentral lists 1 molecular target, including DPP4. Recorded indications include Diabetes mellitus type 2.

• Molecular targets: DPP4 (1 listed in DrugCentral).
• Indications: Diabetes mellitus type 2.
• Molecular formula: C18H20FN5O2; molecular weight 357.39 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Diabetes mellitus type 2

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Dipeptidyl peptidase 4	DPP4	inhibitor	IC50 8.40

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2015-03-26	PMDA	—	Takeda

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Trelagliptin is on its molecule page.

• Molecular formula: C₁₈H₂₀FN₅O₂
• Molecular weight: 357.39 g/mol
• CAS number: 865759-25-7
• InChIKey: IWYJYHUNXVAVAA-OAHLLOKOSA-N
• PubChem CID: 15983988

CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=CC(F)=CC=C2C#N)C1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Trelagliptin used for?

DrugCentral lists the following indications for Trelagliptin: Diabetes mellitus type 2.

How does Trelagliptin work?

Its molecular targets in DrugCentral include DPP4 (inhibitor).

When was Trelagliptin first approved?

Trelagliptin was first approved by the PMDA in 2015.

What is the chemical formula of Trelagliptin?

Trelagliptin has the molecular formula C18H20FN5O2 and a molecular weight of 357.39 g/mol.

Sources

• DrugCentral drug card 5013 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1650443 — compound record and bioactivity
• PubChem CID 15983988 — chemical identifiers
• DrugBank DB15323 — drug record
• FDA UNII Q836OWG55H — substance identity
• UniProt P27487 (DPP4) — target protein

How this page is built: methodology · editorial policy & corrections.